

Minutes
Drug Utilization Review Board Meeting
DATE: 12/14/11



Meeting Purpose: Quarterly Open Board Meeting
Meeting opened at 6:00 P.M. by Chair, Sarah McGee

Agenda Items:

- I. Welcome and Introductory Remarks
- II. Pipeline Preview
- III. MassHealth Drug List Update
- IV. DUR Operational Update
- V. MassHealth Update Dr. Paul Jeffrey

Agenda Item	Discussion	Conclusions/Follow Up
Review of Minutes	The September 2011 Minutes were reviewed and accepted as written at the November Drug Utilization Review (DUR) Board meeting.	Follow Up: N/A
Action	September Minutes approved as noted.	Conclusion: N/A

Agenda Item	Discussion	Conclusions/Follow Up
Pipeline Preview	A continuing education program, Pipeline Preview: A Summary of the Pharmaceutical Pipeline, was presented, and included recent and anticipated FDA approvals, therapeutic class trends and anticipated generic availability.	Follow Up: Informational
Action	Most frequently studied therapeutic classes include: <ul style="list-style-type: none">• Oncology• Central Nervous System• Infectious Disease• Pain/Inflammation• Cardiovascular• Diabetes/Metabolism• Respiratory	Conclusion: N/A

	<p>Significant industry trends include:</p> <ul style="list-style-type: none"> • Oncology – focused genetically guided therapies • Central Nervous System – generic antipsychotics, MS Oral therapies • Infectious Disease – activity in Hepatitis C/Protease Inhibitor class • Pain/Inflammation - abuse deterrent medications emerging • Cardiovascular – growth in anticoagulation/antithrombotic class • Diabetes/Metabolism – inhaled insulin possible • Respiratory – generic montelukast expected in mid-2012 	
--	---	--

Agenda Item	Discussion	Conclusions/Follow Up
MHDL Update	Overview of the Drug List additions effective January 9, 2012, and the drug list changes effective January 23, 2012.	Follow Up: Informational
Action	<p>There are 19 new additions effective January 9, 2012. Changes in Prior Authorization status effective January 23, 2012, were also reviewed.</p> <p>Other updates included:</p> <ul style="list-style-type: none"> • one new PA form: Prostate Cancer Agents • one new therapeutic table: Anticoagulants 	Conclusion: Changes in the MassHealth Drug List will continue to be provided as needed.

Agenda Item	Discussion	Conclusions/Follow Up
DUR Operational Update	Quarterly Operations Update	Follow Up: Informational
Action	<p>DUR Operations monthly workload includes the following:</p> <ul style="list-style-type: none"> • Average of 6,500 PA requests • Average of 7,500 calls <ul style="list-style-type: none"> ○ Average abandonment rate of 1.5 % ○ Average treatment time of 4 minutes • Average of 10 appeals • Average of 500 Provider outreach calls • Top 10 medications include: Suboxone, Lidoderm, Cymbalta, Advair, lansoprazole, Strattera, Singulair, Lyrica, Seroquel, and Nexium • Upon examination of PA approvals, discovered that on average 20-25% of PA approvals are not subsequently utilized. 	Conclusion: Quarterly operational updates will continue to be provided as needed.

Agenda Item	Discussion	Conclusions/Follow Up
MassHealth Update	N/A	<u>Follow Up</u> Informational
Action		Conclusion:

Meeting adjourned at 8:00 P.M.

Respectfully submitted by: Vincent Palumbo, Director of DUR

Date: 3/14/12